News coverage about AstraZeneca plc (NYSE:AZN) has been trending positive this week, Alpha One reports. The research group, a subsidiary of Accern, rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AstraZeneca plc earned a media sentiment score of 0.40 on Alpha One’s scale. Alpha One also assigned headlines about AstraZeneca plc an impact score of 81 out of 100, indicating that recent press coverage is very likely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Alpha One’s analysis:
- BNP Paribas Reiterates “Neutral” Rating for Zpg Plc (ZPLA) (hoyentv.com)
- 3 of my favourite dividend shares: Lloyds, AstraZeneca and BP (investomania.co.uk)
- AstraZeneca’s (AZN) Lung Cancer Drug Gets Full FDA Approval (finance.yahoo.com)
- AstraZeneca plc (AZN) Receives Buy Rating from Liberum Capital (ekosvoice.com)
- Drug spun off by AstraZeneca shows promise in hot flashes (uk.finance.yahoo.com)
A number of research firms recently commented on AZN. Cowen and Company reiterated a “market perform” rating on shares of AstraZeneca plc in a research note on Monday, March 6th. Liberum Capital began coverage on AstraZeneca plc in a research note on Thursday, March 9th. They issued a “buy” rating for the company. Berenberg Bank reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Tuesday, February 21st. Barclays PLC began coverage on AstraZeneca plc in a research note on Tuesday, March 7th. They issued an “overweight” rating for the company. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Tuesday, December 13th. One analyst has rated the stock with a sell rating, six have given a hold rating and twelve have issued a buy rating to the company. AstraZeneca plc presently has a consensus rating of “Buy” and a consensus price target of $35.44.
Shares of AstraZeneca plc (NYSE:AZN) traded down 2.62% during trading on Wednesday, reaching $30.46. 5,355,641 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $30.11 and a 200-day moving average price of $29.14. AstraZeneca plc has a 52-week low of $25.55 and a 52-week high of $35.04. The company has a market capitalization of $77.08 billion, a PE ratio of 22.07 and a beta of 0.77.
AstraZeneca plc (NYSE:AZN) last posted its quarterly earnings data on Thursday, February 2nd. The company reported $1.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.62. AstraZeneca plc had a net margin of 15.21% and a return on equity of 34.30%. The company had revenue of $5.59 billion for the quarter, compared to the consensus estimate of $5.43 billion. During the same quarter in the previous year, the firm posted $0.94 EPS. The business’s revenue was down 12.7% compared to the same quarter last year. On average, equities analysts forecast that AstraZeneca plc will post $1.83 earnings per share for the current year.
The business also recently disclosed a semiannual dividend, which was paid on Monday, March 20th. Stockholders of record on Friday, February 17th were issued a dividend of $0.95 per share. The ex-dividend date was Wednesday, February 15th. This represents a dividend yield of 6.81%. AstraZeneca plc’s payout ratio is 49.64%.
ILLEGAL ACTIVITY NOTICE: This report was originally published by sleekmoney and is the sole property of of sleekmoney. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at http://sleekmoney.com/astrazeneca-plc-azn-given-coverage-optimism-rating-of-0-40/1726982.html.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/astrazeneca-plc-azn-given-coverage-optimism-rating-of-0-40/1726982.html
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.